DEX-M74 Licensing

NZP is presenting on the application of DEX-M74 ManNAc as a potential therapy for HIBM (GNE myopathy) and kidney glomerular diseases at the NCATS R&D Day on Thursday, September 12, 2013 at the Novartis Institutes for Biomedical Research in Cambridge, Massachusetts, U.S.

The Day will provide the unique opportunity for NZP to showcase its DEX-M74 technology that is being incubating in the NCATS drug development program, Therapeutics for Rare and Neglected Diseases (TRND), to an audience of biopharmaceutical companies, venture capital, angel investors, foundations, and others.  Free registration is via :